Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPT-9274 in Relapsed and Refractory Acute Myeloid Leukemia
NCT04914845Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Aug 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of padnarsertib in acute myeloid leukemia (AML) (6 cohorts), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2021; status: completed.
02
Drugs
padnarsertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04914845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914845.